Literature DB >> 33436043

The CXCL12gamma chemokine immobilized by heparan sulfate on stromal niche cells controls adhesion and mediates drug resistance in multiple myeloma.

Marcel Spaargaren1,2, Zemin Ren1,2, Hildo Lantermans1,2, Annemieke Kuil1,2, Willem Kraan1,2, Fernando Arenzana-Seisdedos3, Marie José Kersten2,4, Steven T Pals5,6.   

Abstract

BACKGROUND: The survival and proliferation of multiple myeloma (MM) cells in the bone marrow (BM) critically depend on interaction with stromal cells expressing the chemokine CXCL12. CXCL12 regulates the homing to the BM niche by mediating the transendothelial migration and adhesion/retention of the MM cells. The gamma isoform of CXCL12 (CXCL12γ) has been reported to be highly expressed in mouse BM and to show enhanced biological activity compared to the 'common' CXCL12α isoform, mediated by its unique extended C-terminal domain, which binds heparan sulfate proteoglycans (HSPGs) with an extraordinary high affinity. Here, we investigated the expression of CXCL12γ in human BM and studied its functional role in the interaction of MM cells with BM stromal cells (BMSCs).
METHODS: We assessed CXCL12γ mRNA and protein expression by human BMSCs using qPCR, flow cytometry, and immunohistochemistry. CRISPR-Cas9 was employed to delete CXCL12γ and the heparan sulfate (HS) co-polymerase EXT1 in BMSCs. To study the functional roles of BMSC-derived CXCL12γ and HSPGs in the interaction of MM cells with BMSCs cells, MM cell lines and primary MM cells were co-cultured with BMSCs.
RESULTS: We observed that CXCL12γ is expressed in situ by reticular stromal cells in both normal and MM BM, as well as by primary BMSC isolates and BMSC lines. Importantly, upon secretion, CXCL12γ, unlike the CXCL12α isoform, was retained on the surface of BMSCs. This membrane retention of CXCL12γ is HSPG mediated, since it was completely annulated by CRISPR-Cas9-mediated deletion of the HS co-polymerase EXT1. CXCL12γ expressed by BMSCs and membrane-retained by HSPGs supported robust adhesion of MM cells to the BMSCs. Specific genetic deletion of either CXCL12γ or EXT1 significantly attenuated the ability of BMSCs to support MM cell adhesion and, in addition, impaired their capacity to protect MM cells from bortezomib-induced cell death.
CONCLUSIONS: We show that CXCL12γ is expressed by human BMSCs and upon secretion is retained on their cell surface by HSPGs. The membrane-bound CXCL12γ controls adhesion of MM cells to the stromal niche and mediates drug resistance. These findings designate CXCL12γ and associated HSPGs as partners in mediating MM-niche interaction and as potential therapeutic targets in MM.

Entities:  

Keywords:  Adhesion; Bone marrow stromal cells; CXCL12; Drug resistance; Heparan sulfate proteoglycans; Multiple myeloma

Year:  2021        PMID: 33436043      PMCID: PMC7802348          DOI: 10.1186/s13045-021-01031-3

Source DB:  PubMed          Journal:  J Hematol Oncol        ISSN: 1756-8722            Impact factor:   17.388


  48 in total

Review 1.  Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma.

Authors:  Niels W C J van de Donk; Philippe Moreau; Torben Plesner; Antonio Palumbo; Francesca Gay; Jacob P Laubach; Fabio Malavasi; Hervé Avet-Loiseau; Maria-Victoria Mateos; Pieter Sonneveld; Henk M Lokhorst; Paul G Richardson
Journal:  Blood       Date:  2015-12-02       Impact factor: 22.113

2.  Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches.

Authors:  Tatsuki Sugiyama; Hiroshi Kohara; Mamiko Noda; Takashi Nagasawa
Journal:  Immunity       Date:  2006-12       Impact factor: 31.745

3.  SDF-1 inhibition targets the bone marrow niche for cancer therapy.

Authors:  Aldo M Roccaro; Antonio Sacco; Werner G Purschke; Michele Moschetta; Klaus Buchner; Christian Maasch; Dirk Zboralski; Stefan Zöllner; Stefan Vonhoff; Yuji Mishima; Patricia Maiso; Michaela R Reagan; Silvia Lonardi; Marco Ungari; Fabio Facchetti; Dirk Eulberg; Anna Kruschinski; Axel Vater; Giuseppe Rossi; Sven Klussmann; Irene M Ghobrial
Journal:  Cell Rep       Date:  2014-09-25       Impact factor: 9.423

4.  Chemokine stromal cell-derived factor-1alpha modulates VLA-4 integrin-mediated multiple myeloma cell adhesion to CS-1/fibronectin and VCAM-1.

Authors:  F Sanz-Rodríguez; A Hidalgo; J Teixidó
Journal:  Blood       Date:  2001-01-15       Impact factor: 22.113

Review 5.  Targeting multiple myeloma cells and their bone marrow microenvironment.

Authors:  Guido Pagnucco; Giovanni Cardinale; Francesco Gervasi
Journal:  Ann N Y Acad Sci       Date:  2004-12       Impact factor: 5.691

6.  Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results.

Authors:  Francesca Gay; Valeria Magarotto; Claudia Crippa; Norbert Pescosta; Tommasina Guglielmelli; Federica Cavallo; Sara Pezzatti; Samantha Ferrari; Anna Marina Liberati; Stefania Oliva; Francesca Patriarca; Massimo Offidani; Paola Omedé; Vittorio Montefusco; Maria Teresa Petrucci; Nicola Giuliani; Roberto Passera; Giuseppe Pietrantuono; Mario Boccadoro; Paolo Corradini; Antonio Palumbo
Journal:  Blood       Date:  2013-06-17       Impact factor: 22.113

7.  CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy.

Authors:  Abdel Kareem Azab; Judith M Runnels; Costas Pitsillides; Anne-Sophie Moreau; Feda Azab; Xavier Leleu; Xiaoying Jia; Renee Wright; Beatriz Ospina; Alicia L Carlson; Clemens Alt; Nicholas Burwick; Aldo M Roccaro; Hai T Ngo; Mena Farag; Molly R Melhem; Antonio Sacco; Nikhil C Munshi; Teru Hideshima; Barrett J Rollins; Kenneth C Anderson; Andrew L Kung; Charles P Lin; Irene M Ghobrial
Journal:  Blood       Date:  2009-01-12       Impact factor: 22.113

8.  European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma.

Authors:  Monika Engelhardt; Evangelos Terpos; Martina Kleber; Francesca Gay; Ralph Wäsch; Gareth Morgan; Michele Cavo; Niels van de Donk; Andreas Beilhack; Benedetto Bruno; Hans Erik Johnsen; Roman Hajek; Christoph Driessen; Heinz Ludwig; Meral Beksac; Mario Boccadoro; Christian Straka; Sara Brighen; Martin Gramatzki; Alessandra Larocca; Henk Lokhorst; Valeria Magarotto; Fortunato Morabito; Meletios A Dimopoulos; Hermann Einsele; Pieter Sonneveld; Antonio Palumbo
Journal:  Haematologica       Date:  2014-02       Impact factor: 9.941

Review 9.  Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets.

Authors:  Teru Hideshima; Constantine Mitsiades; Giovanni Tonon; Paul G Richardson; Kenneth C Anderson
Journal:  Nat Rev Cancer       Date:  2007-08       Impact factor: 60.716

10.  CXCL12 and CXCR7 are relevant targets to reverse cell adhesion-mediated drug resistance in multiple myeloma.

Authors:  Johannes M Waldschmidt; Anna Simon; Dagmar Wider; Stefan J Müller; Marie Follo; Gabriele Ihorst; Sarah Decker; Joschka Lorenz; Manik Chatterjee; Abdel K Azab; Justus Duyster; Ralph Wäsch; Monika Engelhardt
Journal:  Br J Haematol       Date:  2017-07-02       Impact factor: 6.998

View more
  3 in total

1.  HBV genome-enriched single cell sequencing revealed heterogeneity in HBV-driven hepatocellular carcinoma (HCC).

Authors:  Wenhui Wang; Yan Chen; Liang Wu; Yi Zhang; Seungyeul Yoo; Quan Chen; Shiping Liu; Yong Hou; Xiao-Ping Chen; Qian Chen; Jun Zhu
Journal:  BMC Med Genomics       Date:  2022-06-16       Impact factor: 3.622

2.  Correction to: The CXCL12gamma chemokine immobilized by heparan sulfate on stromal niche cells controls adhesion and mediates drug resistance in multiple myeloma.

Authors:  Marcel Spaargaren; Steven T Pals; Zemin Ren; Hildo Lantermans; Annemieke Kuil; Willem Kraan; Fernando Arenzana-Seisdedos; Marie José Kersten
Journal:  J Hematol Oncol       Date:  2021-02-16       Impact factor: 17.388

3.  CXCL12/CXCR4 axis supports mitochondrial trafficking in tumor myeloma microenvironment.

Authors:  Cesarina Giallongo; Ilaria Dulcamare; Francesco Di Raimondo; Giuseppe A Palumbo; Daniele Tibullo; Vittorio Del Fabro; Nunzio Vicario; Nunziatina Parrinello; Alessandra Romano; Grazia Scandura; Giacomo Lazzarino; Concetta Conticello; Giovanni Li Volti; Angela Maria Amorini; Giuseppe Musumeci; Michelino Di Rosa; Francesca Polito; Rosaria Oteri; M'hammed Aguennouz; Rosalba Parenti
Journal:  Oncogenesis       Date:  2022-01-21       Impact factor: 7.485

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.